This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200

10 Aug 2021

Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 trial of OVM-200 has been received from the MHRA (Medicines and Healthcare products... Read more

Significant expansion of AI firm Exscientia’s headquarters at TOSP

Significant expansion of AI firm Exscientia’s headquarters at TOSP

04 Aug 2021

Significant expansion of AI firm Exscientia’s headquarters at TOSP Job creation to continue beyond 100 roles added already this year Oxford, UK, August 4 2021 – Exscientia, the clinical stage, artificial intelligence-driven pharmatech company, has announced a significant expansion of its headquarters at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The company, which initially occupied c... Read more

Sensyne Health – Appointment of Chief Scientific Officer

Sensyne Health – Appointment of Chief Scientific Officer

22 Jul 2021

Dr. David Ruau joins Sensyne Health from Bayer Pharmaceuticals Oxford, U.K. 22 July 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the ethical AI company, today announces the appointment of Dr David Ruau to the newly created role of Chief Scientific Officer with effect from 01 September 2021. In this role, David will lead the research effort at Sensyne aimed at applying ethical AI to the improvement of patient care... Read more

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business

20 Jul 2021

Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from Borealis Ventures, Perivoli Innovations, and other institutional and... Read more

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer

15 Jul 2021

T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer Company to be led by award winning, cell therapy expert as it aims to unlock an expansive therapeutic target space by decoding natural T-cell responses in both oncology and autoimmune diseases. Oxford, UK, 15 July 2021 – T-Cypher Bio (‘T-Cypher’, or ‘the Company’), a rapidly emerging private biotech company pioneering a novel approach to TCR... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More